Estudio coste-efectividad de la estrategia empírica antifúngica en pacientes oncohematológicos
E. Romá-Sánchez,José Luis Poveda-Andrés,Javier García-Pellicer,M. Salavert-Lletí,I. Jarque-Ramos +4 more
TLDR
This type of analysis contributes to rationalising the use of antifungal agents in the hospital setting and in high-risk patients such as oncohaematological ones in spite of the limitations of the unconsidered costs.About:
This article is published in Farmacia Hospitalaria.The article was published on 2008-01-01 and is currently open access. It has received 14 citations till now. The article focuses on the topics: Caspofungin & Voriconazole.read more
Citations
More filters
Journal ArticleDOI
Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain.
Santiago Grau,M. Salavert,J. Carlos Pozo Laderas,M. García Vargas,Jon Andoni Barrueta,Nuria Mir +5 more
TL;DR: Treating confirmed candidaemia with anidulafungin is a cost-effective strategy despite increased drug costs, and improved clinical efficacy versus fluconazole is demonstrated.
Journal ArticleDOI
Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients
TL;DR: Therapeutic strategies in treating invasive fungal infections include the initiation of empiric antifungal therapy, triggered by fever that is unresponsive to 48–72 h of broad-spectrum antibiotic therapy in high-risk patients, prior to diagnosis.
Journal ArticleDOI
Pharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey
Stuart J. Turner,Esin Şenol,Ateş Kara,Daoud Al-Badriyeh,Ener Cagri Dinleyici,David C. M. Kong +5 more
TL;DR: There is a strong likelihood that voriconazole is economically more favourable than LAmB in the empiric treatment of IFI in Turkey, and univariate sensitivity analysis highlighted that increasing the duration of vorIconazole by >1.2 days or decreasing LAm B by <1.0 days changes the result.
Journal ArticleDOI
Pharmacoeconomics of voriconazole.
C. Rubio-Terrés,Santiago Grau +1 more
TL;DR: The majority of economic analyses have shown that voriconazole is a more cost-effective alternative in the treatment of invasive fungal infections than the antifungal drugs with which it was compared.
Journal ArticleDOI
Pharmacoeconomic assessment of therapy for invasive aspergillosis
TL;DR: PE evaluations have demonstrated the cost effectiveness and dominance of voriconazole for targeted primary treatment of IA compared with other available agents, and Posaconazole is the most cost‐effective agent for antifungal prophylaxis against IFI and IA.
References
More filters
Journal ArticleDOI
Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International Consensus
Sibel Ascioglu,John H. Rex,B.E. de Pauw,John E. Bennett,J. Bille,F. Crokaert,David W. Denning,J.P. Donnelly,J. E. Edwards,Z. Erjavec,D. Fiere,O. Lortholary,Johan Maertens,Jacques F. Meis,Thomas F. Patterson,J. Ritter,D. Selleslag,Palak Shah,David A. Stevens,Thomas J. Walsh +19 more
TL;DR: A set of research-oriented definitions for the IFIs most often seen and studied in immunocompromised patients with cancer is proposed and three levels of probability are proposed: "proven," "probable," and "possible."
Journal ArticleDOI
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Thomas J. Walsh,Robert W. Finberg,Carola A.S. Arndt,John W. Hiemenz,Cindy L. Schwartz,David C. Bodensteiner,Peter G. Pappas,Nita Seibel,Richard N. Greenberg,Stephen Dummer,Mindy G. Schuster,John S. Holcenberg,William E. Dismukes +12 more
TL;DR: A randomized, double-blind, multicenter trial comparing liposomal amphotericin B with conventional amphoteric in B as empirical antifungal therapy for patients with persistent fever and neutropenia.
Journal ArticleDOI
Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
Thomas J. Walsh,Peter G. Pappas,Drew J. Winston,Hillard M. Lazarus,Finn Bo Petersen,John Raffalli,Saul Yanovich,Patrick J. Stiff,Richard N. Greenberg,Gerald R. Donowitz,Mindy G. Schuster,Annette C. Reboli,John R. Wingard,Carola A.S. Arndt,John F. Reinhardt,Susan Hadley,Robert W. Finberg,Michel Laverdière,John R. Perfect,Gary Garber,Giuseppe Fioritoni,Eli Anaissie,Jeanette Y. Lee +22 more
TL;DR: Voriconazole is a suitable alternative to amphotericin B preparations for empirical antifungal therapy in patients with neutropenia and persistent fever in a randomized, international, multicenter trial.
Journal ArticleDOI
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study.
Livio Pagano,Morena Caira,Anna Candoni,Massimo Offidani,Luana Fianchi,Bruno Martino,Domenico Pastore,Marco Picardi,Alessandro Bonini,Anna Chierichini,Rosa Fanci,Cecilia Caramatti,Rosangela Invernizzi,Daniele Mattei,Maria Enza Mitra,Lorella Melillo,Franco Aversa,Maria Teresa Van Lint,Paolo Falcucci,Caterina Giovanna Valentini,Corrado Girmenia,Annamaria Nosari +21 more
TL;DR: Patients with hematologic malignancies are currently at higher risk of IFI caused by molds than by yeasts, and the incidence of I FI is highest among patients with acute myeloid leukemia.
Journal ArticleDOI
Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive Aspergillosis
David W. Denning,Patricia Ribaud,Noel Milpied,Denis Caillot,Raoul Herbrecht,Eckhard Thiel,Andrea Haas,Markus Ruhnke,Hartmut Lode +8 more
TL;DR: Voriconazole is efficacious in treating acute IA and is proven and probable in 68 patients, and good responses were seen in 60% of those with pulmonary or tracheobronchial IA and 26% of allogeneic stem cell transplant recipients.